• Benvenue Medical

  Participated · Equity · Jan 2016

  Benvenue Medical develops next-generation minimally invasive systems for spine repair, combining expandable implants with novel delivery instruments. Its two commercial products are the Luna 3D Interbody Fusion System (FDA cleared November 2014) and the Kiva VCF Treatment System (FDA cleared January 2014). Luna is a small-profile PEEK implant that expands three-dimensionally within the disc space to restore height via a posterior approach; Kiva is a cylindrical expandable implant shown in a randomized controlled study to restore kyphotic angle and reduce adjacent-level fractures versus balloon kyphoplasty. The company plans to use the financing to accelerate U.S. commercialization of both products. Benvenue is privately held and was founded in 2004; its stated investors include InterWest Partners, Versant Ventures, DeNovo Ventures, Domain Associates, Esquilime Partners and Technology Partners. The treatments the products address have combined global revenues of $9 billion, which the company cites as the market opportunity. Benvenue Medical develops next-generation, minimally invasive expandable implants for spine repair. Its product portfolio includes the Kiva VCF Treatment System, the Blazer-C Vertebral Augmentation System, and the Luna Interbody System. The Luna system has received the CE Mark and is not currently available in the U.S. The company targets a roughly $9 billion global spine device market with devices for degenerative disc disease and vertebral compression fractures. Founded in 2004 and led by CEO Robert Weigle, Benvenue plans to use new funds to build its U.S. commercial presence, scale manufacturing, expand administrative functions, and provide working capital. The Luna system incorporates Benvenue Medical’s proprietary implant technology. Benvenue Medical is a privately held spinal devices maker based in Santa Clara, California, founded in 2004. The company designs and manufactures minimally invasive spinal repair devices, with its flagship Kiva VCF system offering an implant‑based approach to vertebral augmentation for painful vertebral compression fractures. Benvenue announced data showing Kiva was non‑inferior to balloon kyphoplasty for managing pain associated with osteolytic vertebral body metastases and reportedly eliminated incidents of cement leakage. The Kiva System won FDA 510(k) clearance last month and is available in Europe through distribution by Zimmer. Financially, Benvenue recently closed a $3.5 million financing recorded in a regulatory filing. The funds were raised through sales of debt, rights and securities (or rights to acquire securities) from nine unnamed investors. Benvenue Medical develops minimally invasive solutions for spine repair, focusing on treatments for degenerative disc disease and vertebral compression fractures. Its product portfolio includes the Kiva VCF Treatment System, the Blazer Vertebral Augmentation System, and the Luna Interbody Spacer System. The Kiva system is distributed by Zimmer Spine in Europe and is being evaluated in the KAST clinical trial to support a U.S. 510(k) filing. The Blazer system is commercially available in the U.S., while the Luna spacer received CE Mark approval in 2010 and is enrolling patients in a European post-market study (LIFT). The company intends to use new financing to sustain global commercialization of its three products and to advance initiatives to bring its fusion and VCF products to the U.S. market. Benvenue Medical develops minimally invasive solutions for spine repair, including the Kiva system for treating vertebral compression fractures (VCFs). The company offers three minimally invasive products targeting VCFs and degenerative disc disease (DDD). The Kiva system has been used to treat more than 450 vertebral compression fractures globally. Benvenue intends to use new funding to complete enrollment and patient follow-up in the KAST trial (Kiva System as a Vertebral Augmentation Treatment – A Safety and Effectiveness Trial). The company also plans multiple spine product commercialization initiatives in the U.S. and Europe. Benvenue is led by CEO Robert Weigle and was founded in 2004 in Santa Clara, CA, and is entering a roughly $9bn global spinal device market.

• MyoScience

  Participated · Series D · Mar 2012

  Myoscience develops a platform technology called focused cold therapy (FCT) for treating conditions involving nerves. FCT is approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction, treatment of dermatologic conditions and focal cryo‑treatment of tissue, and has been cleared in the United States for pain management and general surgical use. The company plans to use proceeds from its recent financing to commercialize its first indication in Europe: a treatment to reduce dynamic facial lines (forehead wrinkles). Myoscience is led by President & CEO Clint Carnell and is based in Redwood City, California. The company is also working to raise a second tranche of up to $12M in addition to the Series D.

• Spinal Modulation

  Participated · Series D · Jun 2011

  Spinal Modulation’s core product is the Axium Neurostimulator System, which stimulates the dorsal root ganglion (DRG) to provide targeted spinal cord stimulation for chronic, intractable pain, particularly in lower extremities and other hard-to-treat areas. The system’s leads are placed at the DRG and the therapy reportedly uses approximately 95 percent less power than traditional SCS systems. Axium received European CE Mark approval in November 2011 but is not approved for use in the United States. The company has an FDA investigational device exemption (IDE) and anticipated beginning U.S. enrollment in the second half of the year. Spinal Modulation is privately held and based in Menlo Park, CA, and lists Johnson & Johnson Development Corporation, Medtronic, Kleiner Perkins Caufield & Byers, De Novo Ventures, MedVenture Associates, and DFJ InCube Ventures as backers. Clinical evidence and peer-reviewed publications supporting the DRG approach are noted in the announcement. Spinal Modulation is an early-stage medical device company developing a fully implantable spinal cord stimulator system for the treatment of chronic pain. The company has completed development of its first fully implantable spinal cord stimulation system and has initiated international clinical studies. It announced a $30 million Series D financing to support clinical trials and near-term commercialization activities. Proceeds from the financing will be used to conduct clinical trials in the United States and internationally. The company plans to commence commercialization outside the United States in the near future. Headquartered in Menlo Park, California, Spinal Modulation is privately held and backed by strategic and venture investors including Medtronic and several venture firms. Spinal Modulation is a Menlo Park, CA-based medical device company developing next-generation spinal cord stimulator systems. The company's core product is a spinal cord stimulator intended to treat patients suffering from chronic intractable pain. The recently completed financing will support further development of that next-generation system. The company completed a $27.4M Series C financing to fund product advancement. Investors in the round include Johnson & Johnson Development Corporation alongside existing and new venture backers. No operating metrics or revenues were disclosed in the article.

• Pulmonx

  Participated · Equity · Feb 2010

  Pulmonx is a commercial-stage medical technology company focused on minimally-invasive bronchoscopic treatments for severe emphysema, centered on the Zephyr Valve System. The Zephyr Valve is placed via bronchoscopy with no incisions and has randomized-trial data showing improvements in pulmonary function, exercise capacity, breathlessness, and quality of life; it holds FDA breakthrough designation and received FDA premarket approval in June 2018. The Pulmonx solution also includes the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform to identify suitable patients. The company reports physicians in more than 25 countries have used over 76,000 valves to treat more than 19,000 patients, and Zephyr Valves are included in national and global treatment guidelines such as NICE and GOLD. Pulmonx is planning further clinical trials of AeriSeal, a foam-based bronchoscopic lung sealant for patients who cannot be treated with the Zephyr Valve. To support continued commercial expansion and R&D, Pulmonx announced a $66 million financing and secured an additional $17 million in growth capital to refinance existing debt. Pulmonx develops diagnostic and therapeutic pulmonary device technologies, with its core product the Zephyr® Valve for bronchoscopic lung volume reduction in severe emphysema/COPD. The Zephyr Valve is placed in a single bronchoscopic procedure with no incision and has been shown to improve quality of life, reduce shortness of breath, and increase activity. The device received expedited FDA approval as a breakthrough technology and is included in emphysema treatment guidelines from organizations such as GOLD and NICE. Since 2007, more than 15,000 patients have been treated with the Zephyr Valve worldwide. Pulmonx says it is well-positioned to lead the emerging global field of interventional pulmonology, and recent hires are intended to strengthen strategic and operational capabilities. Financially, the company has just closed an oversubscribed $65 million equity financing to support its growth. Pulmonx is a Redwood City, California and Neuchatel, Switzerland-based developer of minimally invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. Led by interim CEO Oern Stuge, M.D., the company develops and markets the Chartis System and the Zephyr endobronchial valve (EBV), a diagnostic and therapeutic solution for emphysema-induced hyperinflation. The Zephyr therapy involves bronchoscopic placement of one-way valves to reduce hyperinflation in diseased portions of the lungs, thereby improving function of healthier lung regions. The Zephyr device received the CE Mark in 2003 and is in an investigational phase in the United States. Pulmonx closed a $20M senior secured term loan with Oxford Finance and intends to use the proceeds to support the U.S. clinical trial of its Zephyr EBV and to expand its business worldwide. Pulmonx develops and markets minimally-invasive devices for diagnosing and treating pulmonary disorders, including the Zephyr Endobronchial Valve (EBV) and the Chartis Pulmonary Assessment System. The company recently secured a $32M equity financing to support its next stage of growth. Both the Zephyr EBV and the Chartis system are CE marked and cleared for sale in Europe and other major international markets. Pulmonx plans to use the proceeds to support the international commercial launch of those products. The financing will also fund expansion of its commercial operations with the goal of reaching positive cash flow and profitability. In conjunction with the round, two investors will join the board of directors to support commercialization efforts. Pulmonx develops medical devices to treat emphysema by inserting a valve into the lung to shut off the diseased portion. The company is using the recent financing to create and advance its emphysema treatment devices. Pulmonx is based in Palo Alto, California, and was founded in 1998. It has previously raised $27 million. The latest financing consists of $3 million in convertible promissory notes. Investors in this round have not been disclosed.

No current team members are available.